Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

CHOO, JAMES

NPI: 1396935227 · KNOXVILLE, TN 37922 · Pain Medicine (Anesthesiology) Physician · NPI assigned 07/26/2007

$167K
Total Medicaid Paid
12,538
Total Claims
11,310
Beneficiaries
10
Codes Billed
2018-01
First Month
2022-02
Last Month

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 3,394 $53K
2019 4,245 $63K
2020 3,591 $51K
2021 1,165 $94.38
2022 143 $0.00

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 5,758 5,098 $100K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 611 555 $21K
99204 Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity 400 370 $18K
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 715 670 $10K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 592 549 $9K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 236 220 $5K
99211 Office or other outpatient visit for the evaluation and management of an established patient, minimal severity 842 804 $4K
64493 20 14 $487.42
99000 3,191 2,880 $0.00
99072 173 150 $0.00